Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Introduction of Orient Europharma

2010

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

General Information

Financial Performance

Business Unit Performance

Business Development

p.2

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

GENERAL INFORMATION

p.3

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

OEP near term Strategy

★ Diversity in Product Portforlios

Presence in Major Asian Countries★

★ Collaboration in Product Dev

p.9

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Major Business Segment

OEP

Oncology

Nutricare

Consumer Health

Cosmetic

Pharma

Orient Pharma

p.12

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Headquarters & Subsidiaries of

ORIENT EUROPHARMA CO., LTD

Subsidiaries: Hong Kong

Philippines

Malaysia

Singapore

China

Headquarters: Taipei, Taiwan

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Infant Nutrition

OEP’s Own－Karihome®

Goat & Cow Series milk powder

Revenue Contribution from Division

12%

1%

Cosmetic

42%

Nutrition Ethical

45%

OtherAdult NutritionOEP’s KariMed®

Adult health supplements

Aesthetic & Skincare products

Licensing-in & Self Development

p.7

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Our Sales Force Overview

8

Countries /Region

Hospital

Specialty

Aesthetic

OTC

Total

Taiwan

51

14

24

43

132

Singapore

2

2

0

9

13

Malaysia

9

3

0

5

17

Hong Kong

3

2

0

7

12

China

0

0

0

20

20

Philippines

175

0

0

0

175

Total

240

21

24

84

369

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

9

Worldwide Partners1982

1984

1986

1988

1994

1996

1999

2001

2003

2004

2005

2006

20082009

2009 2009 2009

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

FINANCIAL PERFORMANCE

p.3

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

2009 Financial Summary

2009 Total Net Revenue USD $ 121M，10% growth over 2008

2009 EPS $4.04 ， highest among all listed Taiwan Pharmaceutical company

2009 vs 2008 Reveneue

•Singapore +16%

•Philippines +11% ( Ranked No. 26 based on IMS revenue)

•Malaysia +5%

•Hong Kong +7%

•China +75%

p.4

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

RevenueUnit：

Million (USD)

2005 2006 2007 2008 2009

Taiwan 64 70 83 93 100

Oversea 6 9 14 18 21

Total 71 79 96 112 121

p.5

0

20

40

60

80

100

120

140

Oversea

Taiwan

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Net Profit After Tax

2005 2006 2007 2008 2009

Net Profit

After Tax3,806,500 4,147,250 5,025,969 7,152,031 8,661,969

Unit：Million (USD)

p.13

-

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Earning Per Share

0

1

2

3

4

5

2005 2006 2007 2008 2009

EPS2.62 2.64 2.83 3.45 4.04

Unit：Dollar (TWD)

p.7

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Leading Company In Taiwan

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Only Local among Fastest Growth

p.15

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Top 10 Among Local MNF

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Top 2 in Mid-sized company in PHL

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

BUSINESS UNIT PERFORMANCE

p.3

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Nutricare Highlights

2009 AC Nielson survey ranked，OEP’s Karihome milk powder series highest in market share 。

Ranked top 3 in Infant supplementary Food segment。

5% Market share in Special Dietary Formulae。

p.13

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Future Strategy & Direction

Interim Strategy /Market Development：

Multiple Branding

New Product Development:

Focus on Infant nutritional Need

Expansion on Special dietary product line

Market Development:

Cont. Expansion in Asia Market

Synergy on promotional resource & standardizing product image.

p.14

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Pharmaceutical

Product Portfolio focused

cardiovascular

Metabolism

Respiratory

Woman’s Health

Central Nervous System

Main drive in 2009 revenue in two major segment : Cardiovascular & Metabolism 。

p.22

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Future Strategy & Direction

Future Strategy:

Continue in expanding market share in cardiovascular & metabolism market。

Continue expansion in Self-payment or not reimbursement market。

2010 Product Portfolio :

Q1 :First generic in Immuno suppressant for organ transplant patients。

Q2: Foster for treatment of Asthma 。

Q3: Collaboration with Japanese Pharma for fast acting DM Type II Disease。

Market Planning:

Current Product: Expansion to Hospital/Clinic channel。

New Product: Synergy with current product to speed up Listing。

p.23

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Oncology

Navelbine IV / Oral for Non-small cell lung cancer & Breast cancer

Nominated by Pierre Fabre as the best performing Territory among Pierre Fabre subsidiary & Licensee for two consecutive years 2008 & 2009

p.16

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Future Strategy & Direction

Active collaboration with partners in International clinical trial to provide the best treatment to the cancer patients in Asia Pacific

Cancer Treatment

Best Supportive Care

Product under Ongoing registration or Clinical Trial：

Loramyc® : Oral Candidiasis

Nanoplatin®:Nano technology of Cisplatin for Pancreatic Cancer.

Multikine®:Head & Neck Cancer Phase III trial scheduled to commenced in Q3, 2010.

p.17

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

COSMETIC Sole Distributor for the world reknown Brand︰

Q-MED︰RESTYLANE ( Hyaulronic Acid Injectable)

Pierre Fabre (France)︰ADERMA，DUCRAY

Dermofarm (Spain)︰CUMLAUDE

Noevir (Japan)︰NOV

Channel Coverage: Hospital, Clinic & Pharmacy。

Established in 2002，CAGR : Two digit growth 。

p.19

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Future Strategy & Direction

2010 Promotional Strategy：

Expansion in Channel

Introduce new skin care concept from Europe : Organic product

Introduce new aesthetic technology

Total Solution！Not just product but total skin care services from in to out

p.20

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Consumer HealthcareMain Concept : Product Development aroud:

Organic Health supplement

Oral Care

Adult Nutrition in Milk & Cereal

Health Supplement – A series of product under (KariMed) developed for Skin whitening & Anti-aging 。

Oral Care- (BUCCOTHERM) make from Natural Spring Water from France以; Total Oral care from Infant to Adult. Due to its unique taste and chemical free feature is the first choice in oral care for infants。

Adult Nutrition in Milk & Cereal– (Vitaglow )series of milk and cereal co-development Lactalis &Global Health。

p.25

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Future Strategy & Direction

Key Strategy in Expansion

Brand Recognition、Channel & Profitbility：

Inc Distributor

Inc Medical activities

Innovation

p.26

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

BUSINESS DEVELOPMENT

p.3

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Phase 1 Phase II Phase III Registration Marketed

Ella (HRA Pharma)

Glufast (Kissei)

Hylase(reimser)

L o r a m y c( H a n d o k )

B r o n u c k( S e n j u )

Vido (Senju)

N a n o p l a t i n(NanoCarrier)

M u l t i k i n e( C e l - S c i )

Licensing - Pipeline Information

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

PRODUCTS AVAILABLE FOR EXPORT

ATC Code

•A02

•A02

•A10

•A10

•C03

•G04

•L04

•N05

NCE/NF/Generic

•Generic

•Generic

•Generic

•Generic

•Generic

•Generic

•Generic

•Generic

Compound

•Granisetron

•Granisetron

•Glibenclamide + Meformin

•Glibenclamide + Meformin

•Metolazone

•Alfuzosin

•Mycophenolate

•Zeleplon

Dosage

•1mg/ml

•1mg/3ml

•2.5mg + 500mg

•5mg + 500mg

•0.5mg

•10mg SR

•250mg

•10mg

Indication

•Supportive Care Therapy

•Supportive Care Therapy

•Type II DM

•Type II DM

•Diuretic

•BPH

•Immunosuppressant

•Insomnia

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

2010 2011 2012 2013 2014 2015

Rifampin-IsoniazidCapsules

ParoxetineCR Tablets

PitavastatinFC Tablets

VancomycinCR Capsules

VancomycinIR Capsules

LansoprazoleODT

Miglitol FC Tablets

ZaleplonDro-Release

R&D Developmental Pipeline - 1

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Oxybutynin/Clonidine

Syrup

OxybutyninXL Tablets

Trospium XR Capsules

RanolazineER Tablets

RizatriptanODT

Nelfinavir/

DMC Capsules

FenofibrateTablets

Zaleplon10mg

Tablets

2010 2011 2012 2013 2014 2015

R&D Developmental Pipeline - 2

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

NelfinavirCapsules

Diltiazem-180 XR

Diltiazem-90 XR

PaliperidoneER Tab

Methy-lphenidateCapsules

RivastigminePatch

Isoniazid

2010 2011 2012 2013 2014 2015

R&D Developmental Pipeline - 3

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Manufacturing

R& D

Orient Pharma

Orient Pharma

p.31

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

37

In-house formulation TechnologiesTwo-Stage Hot-Melt Filling Technology

Transdermal Drug Delivery Technology

Duo-Release Drug Delivery System

Matrix-Controlled Release Drug Delivery System

ODT Drug Delivery System

Fast Release Modified Release

BarrierFast Release Modified Release

a. “CONTROLLED RELEASE OF HYPNOTIC AGENTS” pending. Characteristics: For APIs of low aqueous solubility and to be absorbed systemically.

b. “SUSTAINED DELIVERY OF ANTIBIOTICS” pending.

Characteristics: For APIs of high aqueous solubility and not to be absorbed.

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Project Utilizing Duo – Release System

Partner Product

DURECT (Cupertino, USA) Indication: ADHD

University of Southern California (USC)

Indication: Cancer

Summit PLC (UK)Indication: Sialorrhoea

p.36

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Orient Pharma Facility

Location : Central Science Park

Land Area : 15,200 sq. m (163,400 sq.ft)

Plant I : 1,154 sq. m (12,400 sq. ft)

Plant II : 3 floors with 13,500 sq. m (145,100 sq. ft)

Utility Building : 630 sq. m (6,770 sq. ft )

Design Criteria : FDA, PIC/s & Japanese Standard

p.39

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Location

Taipei

Hu Wei Plant

Airport to Taipei: 35 km (22 mi)

Taipei to Taoyuan: 40 km (25 mi)

Taipei to Huwei: 220 km (138 mi)

60 minutes by high speed railway

from Taipei to Huwei

Taoyuan Plant

p.40

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.41

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.42

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.43

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.44

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.45

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.46

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

p.47

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Construction Schedule

2008/12 Ground

breaking

2010/03 Plant I ready

for operation

2010/05 Bio-batch

production

2010/10 Plant II

ready for operation

p.48

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Landscape

PASS BOX

Plan

t I

Plant II

Warehouse

QC Lab

Utility building

p.49

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Solid Dosage Forms

Tablets: Sugar Coated, Film Coated

Hard Shell Capsule

1, 2 or 3 Stages Hot Melt Filling ;

Hard Shell IR or MR Semisolid capsule

p.50

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Equipment

Machine

Super mixer

Fluid-bed dryer

High-speed tabletting press machine

High-speed doulbe layer tabletting press

machine

Super Coater

2-Stage Hot Melt Capsule filling

machine

Capacity

190~495 L

520 L

28 station 50k~84k tablet/hr

61 station 100k~500k tablet/hr

120~150 kg/batch

30k cap/hr

Brand

Glatt

Glatt

Fette

Fette

Yuan Cheng

Type

VG 600

GPCG PRO 120

P1000

3200i

YC-SC-125FS

Diameter

Max.16mm

Max. 25mm

51

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Annual Capacity

Tablet: 800 million

Capsule: 320 million

Hot Melt Capsule: 60 million

p.52

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

Services

Production/Validation

Analysis/Validation

Stabilities Study

Clinical trial supply Prod & Packaging

CMC Documentation

Distribution

Purchasing

p.53

Inte

grity

Cre

ativity

Solid

arity

Inte

grity

THANK YOU!

p.39